These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 989015)

  • 1. [Enteral availability and therapeutic activity of proscillaridin-4'-methyl ether (author's transl)].
    Krämer KD; Hochrein H
    Arzneimittelforschung; 1976 Apr; 26(4):579-83. PubMed ID: 989015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction of tables facilitating daily control of treatment with proscillaridin A].
    Tytman B
    Pol Tyg Lek; 1979 Dec; 34(49):1917-21. PubMed ID: 575563
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enteral availability and suggested dosages for methyl proscillaridin in decompensated heart patients].
    Krämer KD; Hochrein H
    Verh Dtsch Ges Inn Med; 1975; 81():1669-71. PubMed ID: 1227053
    [No Abstract]   [Full Text] [Related]  

  • 4. Disposition rate of proscillaridin A in man after multiple oral doses.
    Bergdahl B
    Arzneimittelforschung; 1979; 29(2):343-5. PubMed ID: 582147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meproscillarin in patients with renal failure and concomitant heart failure (author's transl)].
    Beckmann H; Belz GG; Quellhorst E
    Med Klin; 1979 Nov; 74(47):1761-6. PubMed ID: 522817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of the relative enteral activity of beta-methyl-digoxin in patients with heart failure (author's transl)].
    Ghabussi P; Krämer KD; Hochrein H
    Med Klin; 1974 May; 69(18):802-5. PubMed ID: 4837409
    [No Abstract]   [Full Text] [Related]  

  • 7. [Determination of individual sensitivity threshold to digitalis glycosides in chronic circulatory insufficiency].
    Tytman B
    Pol Tyg Lek; 1980 May; 35(20):729-32. PubMed ID: 7413492
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma concentrations during repeated intravenous and oral methyl-proscillaridin application in man.
    Belz GG; Nübling H; Belz G
    Arzneimittelforschung; 1976 Feb; 26(2):277-8. PubMed ID: 947212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the practical use of mathematical methods and computer technics for the control of treatment with selected digitalis glycosides].
    Tytman B
    Pol Tyg Lek; 1981 Oct; 36(40):1553-5. PubMed ID: 7335534
    [No Abstract]   [Full Text] [Related]  

  • 10. The bioavailability of methylepoxyproscillaridin (P35): a new semisynthetic cardiac glycoside.
    Bonelli J; Waginger W; Gazo F
    Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):297-9. PubMed ID: 3410606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of mathematical methods and computer technics for monitoring the concentration of digitalis glycosides in the body of patients with symptoms of overdigitalization].
    Tytman B
    Pol Tyg Lek; 1981 Mar; 36(10):373-7. PubMed ID: 7279733
    [No Abstract]   [Full Text] [Related]  

  • 12. [Investigations on the Stability of Proscillaridine, Proscillaridine-3'-methylether and Proscillaridine-4'-methylether in Artificial Gastric and Intestinal Fluids (author's transl)].
    Einig H
    Arzneimittelforschung; 1976; 26(7):1276-9. PubMed ID: 12764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the pharmacokinetics of proscillaridin A in man.
    Andersson KE; Bertler A; Redfors A
    Eur J Clin Pharmacol; 1975 Aug; 8(6):421-5. PubMed ID: 1233243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical trial of proscillaridin A].
    Jenny S; Forster G; Schultheiss M
    Schweiz Med Wochenschr; 1971 Jul; 101(26):972-5. PubMed ID: 5169066
    [No Abstract]   [Full Text] [Related]  

  • 15. [14,15-beta-oxido analog of proscillaridin (HOE 040). A new cardiac glycoside with low arrhythmic activity and greater absorption ratio].
    Lindner E; von Reitzenstein G; Schöne HH
    Arzneimittelforschung; 1979; 29(2):221-6. PubMed ID: 109100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the absorption of proscillaridin A after single oral doses to normal and achlorhydric subjects.
    Andersson KE; Bergdah B; Bertler A; Redfors A
    Acta Pharmacol Toxicol (Copenh); 1977 Jan; 40(1):153-60. PubMed ID: 576356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of proscillaridin A in thoracic duct lymph after single oral doses in man.
    Andersson KE; Bergdahl B; Dencker H; Wettrell G
    Acta Pharmacol Toxicol (Copenh); 1977 Feb; 40(2):280-4. PubMed ID: 576557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on direct effects of proscillaridin A on the electrolyte excretion and transport ATPase in dog kidneys (author's transl)].
    Nishida H
    Hokkaido Igaku Zasshi; 1974 Jul; 49(4):302-6. PubMed ID: 4281758
    [No Abstract]   [Full Text] [Related]  

  • 19. [Threshold of action of meproscillarin following intravenous administration].
    Belz GG; Aust PE
    Med Klin; 1980 Jul; 75(15):551-3. PubMed ID: 7001203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effect of methylepoxyproscillaridin (P35) in patients with congestive myocardiopathy.
    Bonelli J; Magometschnig D; Gazo F
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):243-5. PubMed ID: 3410600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.